Beam Therapeutics Inc. (BEAM) Stock Profile — Insider Trades & Financials

Revenue$114.1M

Net Income$244.3M

EPS$-0.81

Market Cap$2.5B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

John Evans

CEO & Executive Director

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

Employees: 341
Headquarters: CAMBRIDGE, MA, United States
Website: www.beamtx.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

19.73%

ROA?

16.49%

D/E Ratio?

0.20

Op. Margin?

-15.29%

📊

Profitability Ratios

Net Margin?

214.09%

Loading company sections...

Beam Therapeutics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness